Symbols / BLTE Stock $143.36 +2.62% Belite Bio, Inc

Healthcare • Biotechnology • United States • NCM
BLTE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Yu-Hsin Lin M.B.A., Ph.D.
Exch · Country NCM · United States
Market Cap 5.73B
Enterprise Value 5.00B
Income -77.61M
Sales —
FCF (ttm) -9.77M
Book/sh 19.59
Cash/sh 12.52
Employees 41
Insider 10d —
IPO Apr 29, 2022
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 182.62
PEG —
P/S —
P/B 7.32
P/C —
EV/EBITDA -59.55
EV/Sales —
Quick Ratio 49.90
Current Ratio 50.02
Debt/Eq 0.06
LT Debt/Eq —
EPS (ttm) -2.30
EPS next Y 0.79
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-20
Earnings (prior) 2026-03-02
ROA -11.29%
ROE -16.94%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 39.97M
Shs Float 18.48M
Insider Own 44.40%
Instit Own 23.70%
Short Float 5.96%
Short Ratio 8.83
Short Interest 1.23M
52W High 200.00
vs 52W High -28.32%
52W Low 56.10
vs 52W Low 155.54%
Beta -1.19
Impl. Vol. —
Rel Volume 1.59
Avg Volume 157.02K
Volume 250.41K
Target (mean) $211.50
Tgt Median $200.50
Tgt Low $185.00
Tgt High $266.00
# Analysts 8
Recom Strong_buy
Prev Close $139.70
Price $143.36
Change 2.62%
About

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$211.50
Mean price target
2. Current target
$143.36
Latest analyst target
3. DCF / Fair value
$-4.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$143.36
Low
$185.00
High
$266.00
Mean
$211.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-22 reit HC Wainwright & Co. Buy → Buy $200
2026-04-13 reit HC Wainwright & Co. Buy → Buy $200
2026-03-03 main HC Wainwright & Co. Buy → Buy $200
2026-03-03 main Morgan Stanley Overweight → Overweight $201
2026-03-03 main Cantor Fitzgerald Overweight → Overweight $266
2026-01-28 reit HC Wainwright & Co. Buy → Buy $185
2026-01-26 init B of A Securities — → Buy $195
2026-01-06 init Morgan Stanley — → Overweight $191
2025-12-02 up Mizuho Neutral → Outperform $194
2025-12-01 main HC Wainwright & Co. Buy → Buy $185
2025-11-20 init Mizuho — → Neutral $105
2025-10-31 main Benchmark Buy → Buy $132
2025-09-15 main HC Wainwright & Co. Buy → Buy $98
2025-07-03 reit HC Wainwright & Co. Buy → Buy $100
2025-05-15 reit Cantor Fitzgerald Overweight → Overweight —
2025-05-15 reit HC Wainwright & Co. Buy → Buy $100
2025-03-26 reit Benchmark Buy → Buy $80
2025-03-18 reit Cantor Fitzgerald Overweight → Overweight —
2025-03-18 reit HC Wainwright & Co. Buy → Buy $100
2025-01-21 main Benchmark Buy → Buy $79
News
RSS: Latest BLTE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-07 MATA NATHAN L. Officer — 666 $152.45 $102,039
2026-05-06 MATA NATHAN L. Officer — 1,000 $151.57 $153,839
2026-05-05 MATA NATHAN L. Officer — 1,000 $153.92 $155,502
2026-05-04 MATA NATHAN L. Officer — 1,000 $153.50 $155,636
2026-05-01 MATA NATHAN L. Officer — 1,000 $153.89 $155,778
2026-04-30 MATA NATHAN L. Officer — 1,000 $155.68 $156,973
2026-04-29 MATA NATHAN L. Officer — 1,000 $154.58 $155,817
2026-04-28 MATA NATHAN L. Officer — 1,000 $154.65 $159,162
2026-04-27 MATA NATHAN L. Officer — 1,000 $160.83 $162,641
2026-04-24 MATA NATHAN L. Officer — 1,000 $157.86 $159,556
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
84.21
+110.54%
40.00
+26.30%
31.67
+147.00%
12.82
Research And Development
45.38
+51.56%
29.94
+20.51%
24.84
+180.12%
8.87
Selling General And Administration
38.83
+286.11%
10.06
+47.38%
6.82
+72.67%
3.95
General And Administrative Expense
38.83
+286.11%
10.06
+47.38%
6.82
+72.67%
3.95
Other Gand A
38.83
+286.11%
10.06
+47.38%
6.82
+72.67%
3.95
Total Expenses
84.21
+110.54%
40.00
+26.30%
31.67
+147.00%
12.82
Operating Income
-84.21
-110.54%
-40.00
-26.30%
-31.67
-147.00%
-12.82
Total Operating Income As Reported
-84.21
-110.54%
-40.00
-26.30%
-31.67
-147.00%
-12.82
EBITDA
-77.14
-116.28%
-35.67
-14.33%
-31.20
-150.92%
-12.43
Normalized EBITDA
-77.14
-116.28%
-35.67
-14.33%
-31.20
-150.92%
-12.43
Reconciled Depreciation
0.46
+3.34%
0.45
+12.53%
0.40
+101.52%
0.20
EBIT
-77.61
-114.88%
-36.12
-14.30%
-31.60
-150.14%
-12.63
Net Income
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Pretax Income
-77.61
-114.76%
-36.14
-14.28%
-31.62
-150.02%
-12.65
Net Non Operating Interest Income Expense
6.64
+78.58%
3.72
+7485.71%
0.05
+600.00%
0.01
Interest Expense Non Operating
0.00
-90.00%
0.02
-20.00%
0.03
+56.25%
0.02
Net Interest Income
6.64
+78.58%
3.72
+7485.71%
0.05
+600.00%
0.01
Interest Expense
0.00
-90.00%
0.02
-20.00%
0.03
+56.25%
0.02
Interest Income Non Operating
6.64
+77.68%
3.74
+4950.00%
0.07
+221.74%
0.02
Interest Income
6.64
+77.68%
3.74
+4950.00%
0.07
+221.74%
0.02
Other Income Expense
-0.04
-129.08%
0.14
+3625.00%
-0.00
-102.41%
0.17
Other Non Operating Income Expenses
-0.04
-129.08%
0.14
+3625.00%
-0.00
-102.41%
0.17
Tax Provision
0.00
-100.00%
0.01
-33.33%
0.01
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Net Income From Continuing Operation Net Minority Interest
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Net Income From Continuing And Discontinued Operation
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Net Income Continuous Operations
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Normalized Income
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Net Income Common Stockholders
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Diluted EPS
-2.31
-95.76%
-1.18
+0.84%
-1.19
-88.89%
-0.63
Basic EPS
-2.31
-95.76%
-1.18
+0.84%
-1.19
-88.89%
-0.63
Basic Average Shares
33.54
+9.82%
30.54
+14.83%
26.59
+33.12%
19.98
Diluted Average Shares
33.54
+9.82%
30.54
+14.83%
26.59
+33.12%
19.98
Diluted NI Availto Com Stockholders
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
780.56
+413.08%
152.13
+60.74%
94.64
Current Assets
494.27
+236.07%
147.07
+63.52%
89.94
Cash Cash Equivalents And Short Term Investments
492.42
+239.25%
145.15
+64.65%
88.16
Cash And Cash Equivalents
352.93
+1014.16%
31.68
-64.07%
88.16
Cash Equivalents
15.64
0.00
—
Cash Financial
337.29
+964.78%
31.68
-64.07%
88.16
Other Short Term Investments
139.49
+22.93%
113.47
0.00
Receivables
0.72
+20.88%
0.59
-31.49%
0.87
Other Receivables
0.07
—
0.82
Taxes Receivable
0.02
-5.26%
0.02
-38.71%
0.03
Accrued Interest Receivable
0.63
+10.26%
0.57
0.00
Prepaid Assets
1.13
-15.26%
1.33
+45.20%
0.92
Other Current Assets
0.01
—
—
Total Non Current Assets
286.28
+5558.90%
5.06
+7.59%
4.70
Net PPE
0.78
-19.48%
0.96
-25.83%
1.30
Gross PPE
1.28
-1.68%
1.31
-11.99%
1.48
Accumulated Depreciation
-0.51
-48.68%
-0.34
-86.34%
-0.18
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
0.07
+0.00%
0.07
+17.19%
0.06
Construction In Progress
—
—
—
Other Properties
1.02
-2.11%
1.04
-15.33%
1.23
Leases
0.19
+0.00%
0.19
+0.00%
0.19
Goodwill And Other Intangible Assets
4.92
+24.02%
3.96
+20.23%
3.30
Other Intangible Assets
4.92
+24.02%
3.96
+20.23%
3.30
Investments And Advances
280.17
0.00
—
Non Current Deferred Assets
—
—
—
Non Current Prepaid Assets
0.42
+226.92%
0.13
+25.00%
0.10
Other Non Current Assets
—
—
0.06
Total Liabilities Net Minority Interest
10.07
+59.56%
6.31
+49.87%
4.21
Current Liabilities
9.88
+63.34%
6.05
+66.53%
3.63
Payables And Accrued Expenses
7.43
+55.42%
4.78
+95.26%
2.45
Payables
0.01
-61.54%
0.01
—
Current Accrued Expenses
7.43
+55.73%
4.77
+94.73%
2.45
Pensionand Other Post Retirement Benefit Plans Current
1.61
+129.02%
0.70
-3.30%
0.73
Current Debt And Capital Lease Obligation
0.24
-12.68%
0.28
-10.39%
0.31
Current Capital Lease Obligation
0.24
-12.68%
0.28
-10.39%
0.31
Other Current Liabilities
0.60
+107.27%
0.29
+93.96%
0.15
Total Non Current Liabilities Net Minority Interest
0.19
-27.97%
0.26
-54.84%
0.58
Long Term Debt And Capital Lease Obligation
0.19
-27.97%
0.26
-54.84%
0.58
Long Term Capital Lease Obligation
0.19
-27.97%
0.26
-54.84%
0.58
Preferred Securities Outside Stock Equity
—
—
—
Stockholders Equity
770.49
+428.38%
145.82
+61.25%
90.43
Common Stock Equity
770.49
+428.38%
145.82
+61.25%
90.43
Capital Stock
0.00
+33.33%
0.00
+0.00%
0.00
Common Stock
0.00
+33.33%
0.00
+0.00%
0.00
Share Issued
39.35
+23.53%
31.86
+9.16%
29.18
Ordinary Shares Number
39.34
+23.61%
31.83
+9.18%
29.15
Treasury Shares Number
0.01
-57.11%
0.03
-10.78%
0.04
Additional Paid In Capital
956.28
+276.30%
254.12
+56.57%
162.31
Retained Earnings
-185.26
-72.10%
-107.65
-50.55%
-71.50
Gains Losses Not Affecting Retained Earnings
-0.54
+18.79%
-0.66
-76.47%
-0.37
Total Equity Gross Minority Interest
770.49
+428.38%
145.82
+61.25%
90.43
Total Capitalization
770.49
+428.38%
145.82
+61.25%
90.43
Working Capital
484.39
+243.48%
141.02
+63.40%
86.31
Invested Capital
770.49
+428.38%
145.82
+61.25%
90.43
Total Debt
0.43
-20.11%
0.54
-39.39%
0.89
Capital Lease Obligations
0.43
-20.11%
0.54
-39.39%
0.89
Net Tangible Assets
765.57
+439.68%
141.86
+62.80%
87.13
Tangible Book Value
765.57
+439.68%
141.86
+62.80%
87.13
Duefrom Related Parties Current
—
0.00
-100.00%
0.02
Dueto Related Parties Current
0.01
-61.54%
0.01
0.00
Held To Maturity Securities
280.17
0.00
—
Investmentin Financial Assets
280.17
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-36.99
-26.52%
-29.23
+2.02%
-29.84
-160.40%
-11.46
Cash Flow From Continuing Operating Activities
-36.99
-26.52%
-29.23
+2.02%
-29.84
-160.40%
-11.46
Net Income From Continuing Operations
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Depreciation Amortization Depletion
0.46
+3.34%
0.45
+12.53%
0.40
+101.52%
0.20
Depreciation
0.45
+1.57%
0.45
+11.53%
0.40
+101.52%
0.20
Amortization Cash Flow
0.01
+200.00%
0.00
0.00
0.00
Depreciation And Amortization
0.46
+3.34%
0.45
+12.53%
0.40
+101.52%
0.20
Amortization Of Intangibles
0.01
+200.00%
0.00
0.00
0.00
Other Non Cash Items
-1.31
+63.63%
-3.61
—
—
Stock Based Compensation
38.92
+333.06%
8.99
+135.08%
3.82
+157.79%
1.48
Operating Gains Losses
—
—
—
—
Unrealized Gain Loss On Investment Securities
0.00
+100.00%
-0.05
0.00
0.00
Gain Loss On Sale Of PPE
—
—
0.00
0.00
Change In Working Capital
2.55
+125.33%
1.13
+146.68%
-2.43
-394.30%
-0.49
Change In Receivables
-0.07
-189.19%
0.07
+202.78%
-0.07
-125.00%
-0.03
Change In Prepaid Assets
-0.92
+17.45%
-1.11
+68.52%
-3.53
-390.56%
-0.72
Change In Payables And Accrued Expense
3.84
+55.01%
2.48
+74.24%
1.42
+328.01%
0.33
Change In Accrued Expense
3.85
+56.15%
2.46
+73.33%
1.42
+280.97%
0.37
Change In Payable
-0.01
-161.54%
0.01
—
-0.04
Change In Other Current Liabilities
-0.30
+1.31%
-0.30
-25.00%
-0.24
-243.66%
-0.07
Investing Cash Flow
-305.11
-175.94%
-110.57
-175411.11%
-0.06
+84.01%
-0.39
Cash Flow From Continuing Investing Activities
-305.11
-175.94%
-110.57
-175411.11%
-0.06
+84.01%
-0.39
Net PPE Purchase And Sale
-0.18
-53.45%
-0.12
-84.13%
-0.06
+84.01%
-0.39
Purchase Of PPE
-0.18
-53.45%
-0.12
-84.13%
-0.06
+84.01%
-0.39
Sale Of PPE
—
—
0.00
0.00
Capital Expenditure
-0.18
-17.88%
-0.15
-139.68%
-0.06
+84.01%
-0.39
Net Investment Purchase And Sale
-304.93
-176.15%
-110.42
0.00
0.00
Purchase Of Investment
-451.99
-140.08%
-188.26
0.00
0.00
Sale Of Investment
147.06
+88.92%
77.84
0.00
0.00
Net Intangibles Purchase And Sale
0.00
+100.00%
-0.04
0.00
0.00
Purchase Of Intangibles
0.00
+100.00%
-0.04
0.00
0.00
Financing Cash Flow
663.23
+693.39%
83.59
+10.05%
75.96
+105.50%
36.96
Cash Flow From Continuing Financing Activities
663.23
+693.39%
83.59
+10.05%
75.96
+105.50%
36.96
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
182.02
+330.96%
42.24
-23.47%
55.19
+45.27%
37.99
Proceeds From Stock Option Exercised
110.84
+165.63%
41.73
+89.66%
22.00
+733266.67%
0.00
Net Other Financing Charges
370.37
+100745.11%
-0.37
+70.08%
-1.23
-19.42%
-1.03
Changes In Cash
321.14
+671.31%
-56.21
-222.04%
46.06
+83.42%
25.11
Effect Of Exchange Rate Changes
0.12
+143.49%
-0.27
-3088.89%
0.01
+102.46%
-0.37
Beginning Cash Position
31.68
-64.07%
88.16
+109.45%
42.09
+142.67%
17.34
End Cash Position
352.93
+1014.16%
31.68
-64.07%
88.16
+109.45%
42.09
Free Cash Flow
-37.17
-26.48%
-29.39
+1.72%
-29.90
-152.28%
-11.85
Interest Paid Supplemental Data
0.00
0.00
0.00
-100.00%
0.02
Income Tax Paid Supplemental Data
0.00
-100.00%
0.01
-33.33%
0.01
0.00
Common Stock Issuance
182.02
+330.96%
42.24
-23.47%
55.19
+45.27%
37.99
Issuance Of Capital Stock
182.02
+330.96%
42.24
-23.47%
55.19
+45.27%
37.99
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category